First Manhattan’s Lineage Cell Therapeutics LCTX Stock Holding History

First Manhattan’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-94	Closed	-$139	–	1033
2024 Q1	$139	Hold	94	–	–	﹤0.01%	1384
2023 Q4	$102	Hold	94	–	–	﹤0.01%	1413
2023 Q3	$110	Hold	94	–	–	﹤0.01%	1457
2023 Q2	$132	Hold	94	–	–	﹤0.01%	1398
2023 Q1	$141	Hold	94	–	–	﹤0.01%	1489
2022 Q4	$109	Hold	94	–	–	﹤0.01%	1646
2022 Q3	$0	Hold	94	–	–	﹤0.01%	1598
2022 Q2	$0	Hold	94	–	–	﹤0.01%	1620
2022 Q1	$0	Hold	94	–	–	﹤0.01%	1647
2021 Q4	$0	Hold	94	–	–	﹤0.01%	1626
2021 Q3	$0	Sell	94 -2,000	-96%	-$5.13K	﹤0.01%	1635
2021 Q2	$5K	Buy	2,094 +2,000	+2,128%	+$5.17K	﹤0.01%	1383
2021 Q1	$0	Hold	94	–	–	﹤0.01%	1521
2020 Q4	$0	Hold	94	–	–	﹤0.01%	1373
2020 Q3	$0	Hold	94	–	–	﹤0.01%	1398
2020 Q2	$0	Hold	94	–	–	﹤0.01%	1434
2020 Q1	$0	Hold	94	–	–	﹤0.01%	1413
2019 Q4	$0	Hold	94	–	–	﹤0.01%	1338
2019 Q3	$0	Hold	94	–	–	﹤0.01%	1368
2019 Q2	$0	Hold	94	–	–	﹤0.01%	1412
2019 Q1	$0	Buy	+94	New	+$117	﹤0.01%	1429

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

First Manhattan's LCTX Position: Q2 2024 in Review

First Manhattan sold out of Lineage Cell Therapeutics (LCTX) in Q2 2024, closing a stake of 94 shares — an estimated $139 sold.

First Manhattan first reported a position in LCTX in Q1 2019 and held it in 21 quarters. The position peaked at $5K in Q2 2021. 113 funds tracked by Wall St. Rank hold LCTX as of Q2 2024.

First Manhattan reported no remaining Lineage Cell Therapeutics position as of Q2 2024 after selling out during the quarter.
First Manhattan sold 94 Lineage Cell Therapeutics shares in Q2 2024, an estimated $139.
First Manhattan first reported a position in Lineage Cell Therapeutics in Q1 2019 and held it in 21 quarters.
First Manhattan's Lineage Cell Therapeutics position peaked at $5K in Q2 2021.
113 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.